# Fighting for care: how can we better support people with multiple long-term conditions who are accessing community mental health groups? A qualitative interview study within a UK arts therapies trial

**Authors:** Lauren Hounsell, Emma Millard, Emma Medlicott, Emma Fry, Jane Fernandes, Catherine Carr

PMC · DOI: 10.1136/bmjopen-2025-103035 · BMJ Open · 2026-03-03

## TL;DR

This study explores how people with multiple long-term conditions and mental health issues manage to attend and benefit from community therapy groups in the UK.

## Contribution

The study provides new insights into how multiple health conditions affect participation in community mental health groups and offers practical recommendations for clinicians.

## Key findings

- Participants needed to plan ahead and manage symptoms to attend groups.
- Travel to groups was a major challenge requiring support.
- Community groups were highly valued despite the difficulties of attending.

## Abstract

To explore the impact of multiple long-term conditions (MTLCs) and a comorbid mental health condition on decision-making processes, attendance and engagement in NHS community-based therapy groups.

Qualitative in-depth interviews analysed using reflexive codebook analysis as part of a study within a trial.

Secondary community mental health teams from two UK sites.

Purposive sample of 20 participants recruited to a randomised controlled trial of group therapies (arts therapies and counselling) holding a mental health diagnosis and self-reported as having at least one additional physical health condition.

Six themes were constructed: (1) MLTCs influenced arts modality choices and goals; (2) importance of planning ahead to be organised; (3) the journey loomed over participants; (4) the impact of MLTCs on group attendance and participation; (5) the group was valued and important; (6) determination and fighting to get what I need.

Decisions about arts modalities and group attendance were based on a self-perceived level of felt capability. It was important for participants to plan in advance and feel informed ahead of making commitments, enabling them to prepare and manage symptoms. Travelling to the groups was dreaded, and many participants required support with travel in order to attend. Managing symptoms during the journey and groups was challenging; however, participants had a strong determination to uphold the commitment to attend despite their difficulties, as the group was highly valued.

MLTCs have a large impact on people’s capacity to engage in community groups, requiring additional planning and effort. The scale of this impact is often not recognised. Despite this, the benefits of groups for people with MLTCs are especially important, including motivation to leave the house, opportunities for socialisation and a means of reaching one’s own goals. Clinicians are recommended to accommodate the needs of MLTCs when designing community group interventions and consider multiple attendees with MLTCs in the group composition to improve attendance and group engagement.

ISRCTN88805048.

## Full-text entities

- **Genes:** SLC5A2 (solute carrier family 5 member 2) [NCBI Gene 6524] {aka SGLT2}, DPP4 (dipeptidyl peptidase 4) [NCBI Gene 1803] {aka ADABP, ADCP2, CD26, DPPIV, TP103}
- **Diseases:** chronic pain (MESH:D059350), depression (MESH:D003866), Spinal disc damage (MESH:D013124), Musculoskeletal conditions (MESH:D009140), irritable bowel syndrome (MESH:D043183), panic (MESH:D016584), mental health condition (MESH:D000071069), back and leg problem (MESH:D019973), schizotypal and delusional disorders (MESH:D012563), incontinence (MESH:D014549), lethargic (MESH:D004674), arthritis (MESH:D001168), MLTCs (MESH:D000088562), back pain (MESH:D001416), brain disorder (MESH:D001927), Hypertension (MESH:D006973), psychosis (MESH:D011618), cardiovascular diseases (MESH:D002318), fibromyalgia (MESH:D005356), digestive disorders (MESH:D004066), mental health (OMIM:603663), mood disorders (MESH:D019964), COPD (MESH:D029424), fatigue (MESH:D005221), osteoarthritis (MESH:D010003), neurotic, stress-related and somatoform disorders (MESH:D013001), coronary heart disease (MESH:D003327), physical disability (MESH:D059445), pain (MESH:D010146), IBS (MESH:D053560), Diabetes (MESH:D003920), insomnia (MESH:D007319), mental illness (MESH:D001523), anxiety (MESH:D001007), schizophrenia (MESH:D012559), asthma (MESH:D001249)
- **Chemicals:** NaSSA (-), cholesterol (MESH:D002784)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12959026/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12959026/full.md

## References

36 references — full list in the complete paper: https://tomesphere.com/paper/PMC12959026/full.md

---
Source: https://tomesphere.com/paper/PMC12959026